Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal year
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...
Agence France-Presse6d
PHC and CCRM Collaborate to Develop Primary T-Cell Expansion Culture Processes to Enhance Efficiency and Improve Cell Quality
PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary ...
TechBullion7d
PHC Partners with CCRM to Boost Cell Quality with Advanced T-Cell Expansion Solutions
PHC has partnered with CCRM to boost cell quality with advanced T-cell expansion solutions. Takeaway Points  PHC has ...
Gene Therapy: Revolutionizing Medicine By Tackling Diseases At Their Genetic Roots
Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?
AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...
Fierce Biotech2d
Allogene’s phase 1 lymphoma data show CAR-T could ‘leapfrog’ competition: analysts
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...
GEN - Genetic Engineering and Biotechnology News4d
TG Therapeutics Licenses Maxcyte Tech to Develop Cell Therapies for Autoimmune Disease
MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR-T cell therapy program for autoimmune diseases.